esb世博网

On April 13, Sino Biopharm received approval for a new indication for its Anlotinib Hydrochloride Capsules, presumably for differentiated thyroid cancer. This is the fifth indication for the drug to be approved in China.

Anlotinib (trade name: Fukewei) is a new class 1.1 drug developed by CTTQ Pharmaceutical Group, a member company of Sino Biopharm. It has been previously approved in China for the treatment of non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer and medullary thyroid cancer for four major indications. In addition, the combination of anlotinib with chemotherapy, PD-1 and PD-L1 is being widely laid out, with more than 20 clinical trials currently in Phase II or Phase III clinics. In the 2021 ASCO meeting, anlotinib has won the highest number of published data in 13 cancer types and 40 studies, which is a direct proof of the promising future development of anlotinib.